Device Trial Radar · NCT06315023
The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)
Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
450
Planned (sponsor's estimate)
Start
Oct 6, 2023
Primary completion
Jun 7, 2028
Study completion Jun 7, 2032
Sponsor
- Lead sponsor
- EndologixNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Fivos; Massachusetts General Hospital; Society for Vascular Surgery Patient Safety Organization
- First posted
- Mar 18, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this post-market surveillance study will be to evaluate the real-world use of the DETOUR System in treated patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis \> 70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments.
Conditions
- Peripheral Arterial Disease
- Symptomatic Femoropopliteal Lesions
Interventions
DETOUR SystemDevice
Percutaneous Transmural Arterial Bypass Therapy using the DETOUR™ System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom from CD-TLRTime frame: 1 Year
- Freedom from MAETime frame: 30 Days
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Salinas Valley Memorial Hospital
Salinas, California
University of Connecticut
Storrs, Connecticut
Medstar Washington Hospital Center
Washington D.C., District of Columbia
7 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.